Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | TTBK1 | Q5TCY1 | 6/20 | 0.34 |
| ▸ | PAK4 | O96013 | 2/20 | 0.33 |
| ▸ | PGK1 | P00558 | 1/20 | 0.33 |
| ▸ | PIKFYVE | Q9Y2I7 | 1/20 | 0.33 |
| ▸ | GCK | P35557 | 1/20 | 0.33 |
| ▸ | GCKR | Q14397 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.33 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1228595 | 0.86 | PGK1 (0.40) | KMT2AHTTNPC1TTBK1PGK1 | |
| SCHEMBL1203529 | 0.81 | CSF1R (0.39) | TTBK1PAK4PGK1PIKFYVEGCK | |
| SCHEMBL21963753 | 0.78 | HSD17B10 (0.43) | KMT2AHTTNPC1MEN1ALDH1A1 | |
| SCHEMBL2040558 | 0.78 | KMT2A (0.50) | KMT2AHTTNPC1PAK4MEN1 | |
| SCHEMBL2637090 | 0.75 | KMT2A (0.47) | KMT2AHTTNPC1PAK4MEN1 | |
| SCHEMBL17203284 | 0.74 | KMT2A (0.43) | KMT2AHTTNPC1MEN1DYRK1A | |
| SCHEMBL17203338 | 0.74 | KMT2A (0.43) | KMT2AHTTNPC1PGK1GCK | |
| SCHEMBL18430532 | 0.73 | KMT2A (0.46) | KMT2AHTTNPC1PAK4MEN1 | |
| SCHEMBL21787417 | 0.72 | TTBK1 (0.34) | TTBK1PAK4PIKFYVEMAP3K14 | |
| SCHEMBL1254830 | 0.70 | KMT2A (0.50) | KMT2AHTTNPC1PAK4MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109575019-B | Preparation method of 5-bromo-7-azaindole | 苏州闻智生物科技有限公司 | 2020-04-14 | — | — | CN | claimed |
| CN-109575019-B | Preparation method of 5-bromo-7-azaindole | 苏州闻智生物科技有限公司 | 2020-04-14 | — | — | CN | disclosed |
| EP-2462116-B1 | PROCESS FOR THE MANUFACTURE OF PHARMACEUTICALLY ACTIVE COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2014-09-17 | — | — | EP | disclosed |
| EP-2462116-B1 | PROCESS FOR THE MANUFACTURE OF PHARMACEUTICALLY ACTIVE COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2014-09-17 | — | — | EP | disclosed |
| US-8741920-B2 | Process for the manufacture of pharmaceutically active compounds | HOFFMANN-LA ROCHE, INC. (US) | 2014-06-03 | — | — | US | disclosed |
| US-8741920-B2 | Process for the manufacture of pharmaceutically active compounds | HOFFMANN-LA ROCHE, INC. (US) | 2014-06-03 | — | — | US | disclosed |
| US-8741920-B2 | Process for the manufacture of pharmaceutically active compounds | HOFFMANN-LA ROCHE, INC. (US) | 2014-06-03 | — | — | US | disclosed |
| US-8530661-B2 | Process for the manufacture of pharmaceutically active compounds | HOFFMANN-LA ROCHE, INC. (US) | 2013-09-10 | — | — | US | disclosed |
| US-8530661-B2 | Process for the manufacture of pharmaceutically active compounds | HOFFMANN-LA ROCHE, INC. (US) | 2013-09-10 | — | — | US | disclosed |
| US-8530661-B2 | Process for the manufacture of pharmaceutically active compounds | HOFFMANN-LA ROCHE, INC. (US) | 2013-09-10 | — | — | US | disclosed |
| US-20130005761-A1 | PROCESS FOR THE MANUFACTURE OF PHARMACEUTICALLY ACTIVE COMPOUNDS | HOFFMANN-LA ROCHE INC. | 2013-01-03 | — | — | US | disclosed |
| US-20130005761-A1 | PROCESS FOR THE MANUFACTURE OF PHARMACEUTICALLY ACTIVE COMPOUNDS | HOFFMANN-LA ROCHE INC. | 2013-01-03 | — | — | US | disclosed |
| US-8329724-B2 | Process for the manufacture of pharmaceutically active compounds | HOFFMANN-LA ROCHE INC. (US) | 2012-12-11 | — | — | US | disclosed |
| US-8329724-B2 | Process for the manufacture of pharmaceutically active compounds | HOFFMANN-LA ROCHE INC. (US) | 2012-12-11 | — | — | US | disclosed |
| US-8329724-B2 | Process for the manufacture of pharmaceutically active compounds | HOFFMANN-LA ROCHE INC. (US) | 2012-12-11 | — | — | US | disclosed |
| EP-2462116-A2 | PROCESS FOR THE MANUFACTURE OF PHARMACEUTICALLY ACTIVE COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2012-06-13 | — | — | EP | disclosed |
| WO-2011015522-A2 | PROCESS FOR THE MANUFACTURE OF PHARMACEUTICALLY ACTIVE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-02-10 | — | — | WO | disclosed |
| US-20110028511-A1 | PROCESS FOR THE MANUFACTURE OF PHARMACEUTICALLY ACTIVE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-02-03 | — | — | US | disclosed |
| US-20110028511-A1 | PROCESS FOR THE MANUFACTURE OF PHARMACEUTICALLY ACTIVE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-02-03 | — | — | US | disclosed |
| US-20110028511-A1 | PROCESS FOR THE MANUFACTURE OF PHARMACEUTICALLY ACTIVE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028511-A1 | PROCESS FOR THE MANUFACTURE OF PHARMACEUTICALLY ACTIVE COMPOUNDS | CYP2F1, CYP1B1, CYP7A1 | KMT2A 4277/4885HTT 3121/4885NPC1 130/4885 |
| US-20130005761-A1 | PROCESS FOR THE MANUFACTURE OF PHARMACEUTICALLY ACTIVE COMPOUNDS | CYP1B1, CYP4B1, CYP2C19 | KMT2A 4181/4885HTT 2492/4885NPC1 174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.